Galapagos delivers candidate drug in GSK alliance, receives €6.7 million
This latest pre-clinical candidate is a small molecule that meets the chemical and biological criteria set by GSK for a potential new medicine. Galapagos will now start scale-up chemistry and comprehensive safety evaluation, with the aim to initiate Phase I clinical trials in early 2012.
"The arthritis alliance with GSK has been very fruitful in delivering promising candidate drugs," said Onno van de Stolpe, CEO of Galapagos. "In this alliance, we currently have two clinical trials, with plans to progress this new candidate into the clinic next year."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.